RxDoctor Payments DataLook up a doctor →

Tanya Dyer

Family · Hickory, NCNPI 1851568125

Payments from drug & device makers

$20,569in general payments, 2019–2025

Across 1,400 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$2K
  • AstraZeneca$2K
  • Amgen$2K
  • Kowa Pharmaceuticals America, Inc.$1K
  • Bayer$1K
  • plus $10K from 53 others

What the payments were for

  • Consulting fees$1,0005%
  • Food & beverage$19,06793%
  • Education$5032%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk254$2,553
AbbVie188$2,169
AstraZeneca105$2,026
Amgen38$1,564
Kowa Pharmaceuticals America, Inc.102$1,089
Bayer72$1,033
Lilly USA, LLC65$926
Pfizer62$822
Astellas Pharma US Inc25$772
Boehringer Ingelheim54$720
Otsuka America Pharmaceutical, Inc.38$595
Takeda Pharmaceuticals U.S.A., Inc.43$534
Sumitomo Pharma America, Inc.24$525
Axsome Therapeutics, Inc.28$406
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC25$361
GSK14$335
Clarus Therapeutics Inc.22$309
Tolmar, Inc.18$264
Novartis11$230
Corcept Therapeutics14$229
Idorsia Pharmaceuticals US Inc12$215
Biohaven Pharmaceuticals, Inc.16$185
Amarin Pharma, Inc.14$184
Abbott9$182
Biohaven Pharmaceutical Holding Company Ltd.10$181
Phathom Pharmaceuticals, Inc.11$160
Sanofi-aventis U.S. LLC9$156
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$155
Johnson & Johnson10$148
Azurity Pharmaceuticals, Inc.7$132
Lundbeck LLC7$125
Dexcom, Inc.6$122
Currax Pharmaceuticals LLC8$115
Corium, LLC13$108
Teva Pharmaceuticals USA, Inc.7$101
Amneal Pharmaceuticals LLC5$80
Bausch Health US, LLC5$73
Esperion Therapeutics, Inc.5$71
Vanda Pharmaceuticals Inc.3$58
Forte Bio-pharma LLC2$56
Exact Sciences3$50
Supernus Pharmaceuticals, Inc.2$42
Sunovion Pharmaceuticals Inc.2$41
Almatica Pharma LLC3$40
Antares Pharma, Inc.2$36
Verity Pharmaceuticals Inc.2$35
Radius Health, Inc.2$32
Scynexis, Inc.2$31
Tris Pharma Inc2$29
Ironshore Pharmaceuticals Inc.2$26
Inari Medical, Inc.1$20
Endo Pharmaceuticals Inc.1$19
Noven Therapeutics, LLC1$17
Dynavax Technologies Corporation1$15
Ironwood Pharmaceuticals, Inc1$15
Genentech USA, Inc.2$14
Arbor Pharmaceuticals, Inc.1$14
Neos Therapeutics, LP1$13
Cequr Corporation1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,569 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$45,203
Medicare patients
106
Services billed
1,107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide112$116,123
EliquisApixaban38$44,150
Tresiba Flextouch U-200Insulin Degludec29$35,743
MounjaroTirzepatide25$27,343
JanuviaSitagliptin Phosphate21$20,251
FarxigaDapagliflozin Propanediol23$18,027
Repatha SyringeEvolocumab13$14,988
RexultiBrexpiprazole14$12,076
MyrbetriqMirabegron12$8,868
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen264$8,267
Insulin Lispro Kwikpen U-100Insulin Lispro12$7,685
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen217$7,614
VascepaIcosapent Ethyl21$7,490
NamzaricMemantine Hcl/Donepezil Hcl11$6,109
Lisdexamfetamine Dimesylate22$5,384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,553$116,123112 claims
PfizerEliquis$822$44,15038 claims
Lilly USA, LLCMounjaro$926$27,34325 claims
AstraZenecaFarxiga$2,026$18,02723 claims
Otsuka America Pharmaceutical, Inc.Rexulti$595$12,07614 claims
AbbVieNamzaric, Synthroid$2,169$9,61151 claims
Astellas Pharma US IncMyrbetriq$772$8,86812 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$80$1,733295 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →